ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates

Over the last four quarters, the company has surpassed consensus EPS estimates two times. ADC Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $18.84 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.58%. This compares to year-ago revenues of $17.41 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the ...